nodes	percent_of_prediction	percent_of_DWPC	metapath
Nilotinib—ABCB1—ulcerative colitis	0.116	1	CbGaD
Nilotinib—ABCG2—Sulfasalazine—ulcerative colitis	0.0277	0.0782	CbGbCtD
Nilotinib—CYP2B6—Nicotine—ulcerative colitis	0.025	0.0707	CbGbCtD
Nilotinib—CYP2B6—Cholecalciferol—ulcerative colitis	0.0225	0.0634	CbGbCtD
Nilotinib—ABCG2—Hydrocortisone—ulcerative colitis	0.0222	0.0628	CbGbCtD
Nilotinib—CYP2C8—Nicotine—ulcerative colitis	0.019	0.0536	CbGbCtD
Nilotinib—CYP3A4—Budesonide—ulcerative colitis	0.0177	0.0499	CbGbCtD
Nilotinib—CYP2C8—Cholecalciferol—ulcerative colitis	0.017	0.048	CbGbCtD
Nilotinib—ABCG2—Dexamethasone—ulcerative colitis	0.0138	0.039	CbGbCtD
Nilotinib—CYP2C9—Nicotine—ulcerative colitis	0.0132	0.0374	CbGbCtD
Nilotinib—ABCB1—Methylprednisolone—ulcerative colitis	0.0132	0.0372	CbGbCtD
Nilotinib—CYP2D6—Nicotine—ulcerative colitis	0.0121	0.0342	CbGbCtD
Nilotinib—CYP2C9—Cholecalciferol—ulcerative colitis	0.0119	0.0335	CbGbCtD
Nilotinib—CYP2C8—Hydrocortisone—ulcerative colitis	0.0118	0.0334	CbGbCtD
Nilotinib—CYP2D6—Cholecalciferol—ulcerative colitis	0.0109	0.0306	CbGbCtD
Nilotinib—CYP2B6—Dexamethasone—ulcerative colitis	0.00972	0.0275	CbGbCtD
Nilotinib—ABCB1—Betamethasone—ulcerative colitis	0.00857	0.0242	CbGbCtD
Nilotinib—ABCB1—Prednisolone—ulcerative colitis	0.00845	0.0239	CbGbCtD
Nilotinib—ABCB1—Hydrocortisone—ulcerative colitis	0.00801	0.0226	CbGbCtD
Nilotinib—ABCB1—Prednisone—ulcerative colitis	0.00798	0.0225	CbGbCtD
Nilotinib—KIT—myenteric nerve plexus—ulcerative colitis	0.00795	0.0892	CbGeAlD
Nilotinib—CYP3A4—Methylprednisolone—ulcerative colitis	0.0079	0.0223	CbGbCtD
Nilotinib—CYP3A4—Nicotine—ulcerative colitis	0.00769	0.0217	CbGbCtD
Nilotinib—CYP2C8—Dexamethasone—ulcerative colitis	0.00736	0.0208	CbGbCtD
Nilotinib—CYP3A4—Cholecalciferol—ulcerative colitis	0.0069	0.0195	CbGbCtD
Nilotinib—CYP3A4—Triamcinolone—ulcerative colitis	0.00598	0.0169	CbGbCtD
Nilotinib—CYP2C9—Dexamethasone—ulcerative colitis	0.00514	0.0145	CbGbCtD
Nilotinib—CYP3A4—Betamethasone—ulcerative colitis	0.00513	0.0145	CbGbCtD
Nilotinib—CYP3A4—Prednisolone—ulcerative colitis	0.00507	0.0143	CbGbCtD
Nilotinib—ABCB1—Dexamethasone—ulcerative colitis	0.00498	0.0141	CbGbCtD
Nilotinib—CYP3A4—Hydrocortisone—ulcerative colitis	0.0048	0.0136	CbGbCtD
Nilotinib—CYP3A4—Prednisone—ulcerative colitis	0.00478	0.0135	CbGbCtD
Nilotinib—CYP2D6—Dexamethasone—ulcerative colitis	0.0047	0.0133	CbGbCtD
Nilotinib—CYP3A4—Dexamethasone—ulcerative colitis	0.00299	0.00843	CbGbCtD
Nilotinib—CDC42BPB—smooth muscle tissue—ulcerative colitis	0.00202	0.0227	CbGeAlD
Nilotinib—FRK—lymphoid tissue—ulcerative colitis	0.00191	0.0215	CbGeAlD
Nilotinib—MAPK8—epithelium—ulcerative colitis	0.0019	0.0213	CbGeAlD
Nilotinib—BLK—lymphoid tissue—ulcerative colitis	0.00185	0.0207	CbGeAlD
Nilotinib—MAPK8—smooth muscle tissue—ulcerative colitis	0.00183	0.0205	CbGeAlD
Nilotinib—EPHB2—lymphoid tissue—ulcerative colitis	0.00183	0.0205	CbGeAlD
Nilotinib—EPHB2—digestive system—ulcerative colitis	0.0018	0.0203	CbGeAlD
Nilotinib—TIE1—epithelium—ulcerative colitis	0.00164	0.0185	CbGeAlD
Nilotinib—CDC42BPB—digestive system—ulcerative colitis	0.0016	0.0179	CbGeAlD
Nilotinib—TIE1—smooth muscle tissue—ulcerative colitis	0.00158	0.0178	CbGeAlD
Nilotinib—MAPK8—lymphoid tissue—ulcerative colitis	0.00146	0.0164	CbGeAlD
Nilotinib—MAPK8—digestive system—ulcerative colitis	0.00144	0.0162	CbGeAlD
Nilotinib—FRK—liver—ulcerative colitis	0.00141	0.0158	CbGeAlD
Nilotinib—LYN—lymphoid tissue—ulcerative colitis	0.00135	0.0151	CbGeAlD
Nilotinib—MAP4K1—lymphoid tissue—ulcerative colitis	0.00133	0.0149	CbGeAlD
Nilotinib—MAPK14—epithelium—ulcerative colitis	0.0012	0.0135	CbGeAlD
Nilotinib—EPHB3—digestive system—ulcerative colitis	0.00119	0.0134	CbGeAlD
Nilotinib—CDC42BPB—liver—ulcerative colitis	0.00119	0.0133	CbGeAlD
Nilotinib—MAPK14—smooth muscle tissue—ulcerative colitis	0.00116	0.013	CbGeAlD
Nilotinib—EPHB4—epithelium—ulcerative colitis	0.00114	0.0128	CbGeAlD
Nilotinib—EPHA2—epithelium—ulcerative colitis	0.00112	0.0126	CbGeAlD
Nilotinib—HCK—lymphoid tissue—ulcerative colitis	0.00111	0.0124	CbGeAlD
Nilotinib—EPHB4—smooth muscle tissue—ulcerative colitis	0.0011	0.0123	CbGeAlD
Nilotinib—HCK—digestive system—ulcerative colitis	0.00109	0.0123	CbGeAlD
Nilotinib—TEK—epithelium—ulcerative colitis	0.00109	0.0123	CbGeAlD
Nilotinib—MAPK8—liver—ulcerative colitis	0.00107	0.0121	CbGeAlD
Nilotinib—CA7—digestive system—ulcerative colitis	0.00107	0.012	CbGeAlD
Nilotinib—TEK—smooth muscle tissue—ulcerative colitis	0.00105	0.0118	CbGeAlD
Nilotinib—EPHB2—Diflorasone—Budesonide—ulcerative colitis	0.000993	0.265	CbGdCrCtD
Nilotinib—LYN—liver—ulcerative colitis	0.000992	0.0111	CbGeAlD
Nilotinib—Imatinib—PTGS1—ulcerative colitis	0.000967	0.359	CrCbGaD
Nilotinib—PDGFRA—smooth muscle tissue—ulcerative colitis	0.000954	0.0107	CbGeAlD
Nilotinib—CA9—digestive system—ulcerative colitis	0.00094	0.0105	CbGeAlD
Nilotinib—TIE1—liver—ulcerative colitis	0.000932	0.0105	CbGeAlD
Nilotinib—MAPK14—lymphoid tissue—ulcerative colitis	0.000927	0.0104	CbGeAlD
Nilotinib—FGR—lymphoid tissue—ulcerative colitis	0.000924	0.0104	CbGeAlD
Nilotinib—MAPK14—digestive system—ulcerative colitis	0.000916	0.0103	CbGeAlD
Nilotinib—FGR—digestive system—ulcerative colitis	0.000912	0.0102	CbGeAlD
Nilotinib—BRAF—liver—ulcerative colitis	0.000893	0.01	CbGeAlD
Nilotinib—EPHB4—digestive system—ulcerative colitis	0.000868	0.00975	CbGeAlD
Nilotinib—EPHA2—lymphoid tissue—ulcerative colitis	0.000863	0.00968	CbGeAlD
Nilotinib—EPHA2—digestive system—ulcerative colitis	0.000852	0.00956	CbGeAlD
Nilotinib—TEK—lymphoid tissue—ulcerative colitis	0.000841	0.00944	CbGeAlD
Nilotinib—CSF1R—smooth muscle tissue—ulcerative colitis	0.00084	0.00942	CbGeAlD
Nilotinib—HCK—liver—ulcerative colitis	0.000814	0.00914	CbGeAlD
Nilotinib—ABL2—liver—ulcerative colitis	0.000809	0.00908	CbGeAlD
Nilotinib—KIT—epithelium—ulcerative colitis	0.000791	0.00888	CbGeAlD
Nilotinib—PDGFRB—epithelium—ulcerative colitis	0.000773	0.00867	CbGeAlD
Nilotinib—Ponatinib—ABCB1—ulcerative colitis	0.000763	0.284	CrCbGaD
Nilotinib—KIT—smooth muscle tissue—ulcerative colitis	0.000762	0.00856	CbGeAlD
Nilotinib—PDGFRA—lymphoid tissue—ulcerative colitis	0.000762	0.00856	CbGeAlD
Nilotinib—PDGFRA—digestive system—ulcerative colitis	0.000753	0.00845	CbGeAlD
Nilotinib—PDGFRB—smooth muscle tissue—ulcerative colitis	0.000745	0.00836	CbGeAlD
Nilotinib—CA3—liver—ulcerative colitis	0.000731	0.00821	CbGeAlD
Nilotinib—UGT1A1—digestive system—ulcerative colitis	0.000718	0.00806	CbGeAlD
Nilotinib—CA12—digestive system—ulcerative colitis	0.000695	0.0078	CbGeAlD
Nilotinib—MAPK14—liver—ulcerative colitis	0.000683	0.00766	CbGeAlD
Nilotinib—LCK—liver—ulcerative colitis	0.00068	0.00763	CbGeAlD
Nilotinib—FGR—liver—ulcerative colitis	0.00068	0.00763	CbGeAlD
Nilotinib—CSF1R—lymphoid tissue—ulcerative colitis	0.000671	0.00753	CbGeAlD
Nilotinib—CA14—liver—ulcerative colitis	0.000664	0.00745	CbGeAlD
Nilotinib—ABL1—smooth muscle tissue—ulcerative colitis	0.000664	0.00745	CbGeAlD
Nilotinib—CSF1R—digestive system—ulcerative colitis	0.000663	0.00744	CbGeAlD
Nilotinib—EPHB4—liver—ulcerative colitis	0.000647	0.00726	CbGeAlD
Nilotinib—EPHA2—liver—ulcerative colitis	0.000635	0.00712	CbGeAlD
Nilotinib—TEK—liver—ulcerative colitis	0.000619	0.00695	CbGeAlD
Nilotinib—KIT—lymphoid tissue—ulcerative colitis	0.000609	0.00684	CbGeAlD
Nilotinib—KIT—digestive system—ulcerative colitis	0.000602	0.00676	CbGeAlD
Nilotinib—PDGFRB—lymphoid tissue—ulcerative colitis	0.000595	0.00668	CbGeAlD
Nilotinib—PDGFRB—digestive system—ulcerative colitis	0.000588	0.0066	CbGeAlD
Nilotinib—PDGFRA—liver—ulcerative colitis	0.000561	0.0063	CbGeAlD
Nilotinib—CA1—lymphoid tissue—ulcerative colitis	0.000557	0.00626	CbGeAlD
Nilotinib—CA1—digestive system—ulcerative colitis	0.000551	0.00618	CbGeAlD
Nilotinib—UGT1A1—liver—ulcerative colitis	0.000535	0.00601	CbGeAlD
Nilotinib—ABL1—lymphoid tissue—ulcerative colitis	0.000531	0.00595	CbGeAlD
Nilotinib—ABL1—digestive system—ulcerative colitis	0.000524	0.00588	CbGeAlD
Nilotinib—MAP2K5—liver—ulcerative colitis	0.000506	0.00568	CbGeAlD
Nilotinib—CSF1R—liver—ulcerative colitis	0.000494	0.00554	CbGeAlD
Nilotinib—Imatinib—ALB—ulcerative colitis	0.000492	0.183	CrCbGaD
Nilotinib—EPHB2—Diflorasone—Methylprednisolone—ulcerative colitis	0.00048	0.128	CbGdCrCtD
Nilotinib—EPHB2—Diflorasone—Dexamethasone—ulcerative colitis	0.000472	0.126	CbGdCrCtD
Nilotinib—EPHB2—Diflorasone—Betamethasone—ulcerative colitis	0.000472	0.126	CbGdCrCtD
Nilotinib—Imatinib—ABCB1—ulcerative colitis	0.00047	0.175	CrCbGaD
Nilotinib—CA2—epithelium—ulcerative colitis	0.000469	0.00526	CbGeAlD
Nilotinib—EPHB2—Diflorasone—Triamcinolone—ulcerative colitis	0.000461	0.123	CbGdCrCtD
Nilotinib—CA2—smooth muscle tissue—ulcerative colitis	0.000452	0.00507	CbGeAlD
Nilotinib—KIT—liver—ulcerative colitis	0.000448	0.00503	CbGeAlD
Nilotinib—PDGFRB—liver—ulcerative colitis	0.000438	0.00492	CbGeAlD
Nilotinib—EPHB2—Diflorasone—Prednisone—ulcerative colitis	0.000438	0.117	CbGdCrCtD
Nilotinib—CA4—digestive system—ulcerative colitis	0.00043	0.00483	CbGeAlD
Nilotinib—EPHB2—Diflorasone—Prednisolone—ulcerative colitis	0.000427	0.114	CbGdCrCtD
Nilotinib—CA1—liver—ulcerative colitis	0.00041	0.0046	CbGeAlD
Nilotinib—ABL1—liver—ulcerative colitis	0.00039	0.00438	CbGeAlD
Nilotinib—CA2—lymphoid tissue—ulcerative colitis	0.000361	0.00405	CbGeAlD
Nilotinib—CA2—digestive system—ulcerative colitis	0.000357	0.004	CbGeAlD
Nilotinib—CYP2B6—lymphoid tissue—ulcerative colitis	0.000309	0.00346	CbGeAlD
Nilotinib—CYP2B6—digestive system—ulcerative colitis	0.000305	0.00342	CbGeAlD
Nilotinib—CYP2C9—digestive system—ulcerative colitis	0.000302	0.00339	CbGeAlD
Nilotinib—CA2—liver—ulcerative colitis	0.000266	0.00298	CbGeAlD
Nilotinib—CYP2C8—liver—ulcerative colitis	0.000253	0.00284	CbGeAlD
Nilotinib—ABCG2—liver—ulcerative colitis	0.000246	0.00276	CbGeAlD
Nilotinib—CYP3A4—digestive system—ulcerative colitis	0.00023	0.00258	CbGeAlD
Nilotinib—CYP2B6—liver—ulcerative colitis	0.000227	0.00255	CbGeAlD
Nilotinib—CYP2D6—digestive system—ulcerative colitis	0.000227	0.00254	CbGeAlD
Nilotinib—CYP2C9—liver—ulcerative colitis	0.000225	0.00252	CbGeAlD
Nilotinib—ABCB1—epithelium—ulcerative colitis	0.000214	0.0024	CbGeAlD
Nilotinib—CYP3A4—liver—ulcerative colitis	0.000172	0.00192	CbGeAlD
Nilotinib—CYP2D6—liver—ulcerative colitis	0.000169	0.00189	CbGeAlD
Nilotinib—ABCB1—lymphoid tissue—ulcerative colitis	0.000165	0.00185	CbGeAlD
Nilotinib—ABCB1—digestive system—ulcerative colitis	0.000163	0.00183	CbGeAlD
Nilotinib—ABCB1—liver—ulcerative colitis	0.000121	0.00136	CbGeAlD
Nilotinib—Tachycardia—Prednisolone—ulcerative colitis	7.62e-05	0.000342	CcSEcCtD
Nilotinib—Hypertension—Triamcinolone—ulcerative colitis	7.59e-05	0.000341	CcSEcCtD
Nilotinib—Pruritus—Mesalazine—ulcerative colitis	7.58e-05	0.000341	CcSEcCtD
Nilotinib—Hypertension—Methylprednisolone—ulcerative colitis	7.58e-05	0.000341	CcSEcCtD
Nilotinib—Infection—Hydrocortisone—ulcerative colitis	7.57e-05	0.00034	CcSEcCtD
Nilotinib—Hyperhidrosis—Prednisolone—ulcerative colitis	7.54e-05	0.000339	CcSEcCtD
Nilotinib—Shock—Hydrocortisone—ulcerative colitis	7.5e-05	0.000337	CcSEcCtD
Nilotinib—Myalgia—Triamcinolone—ulcerative colitis	7.49e-05	0.000337	CcSEcCtD
Nilotinib—Vomiting—Azathioprine—ulcerative colitis	7.48e-05	0.000336	CcSEcCtD
Nilotinib—Nervous system disorder—Hydrocortisone—ulcerative colitis	7.48e-05	0.000336	CcSEcCtD
Nilotinib—Arthralgia—Methylprednisolone—ulcerative colitis	7.47e-05	0.000336	CcSEcCtD
Nilotinib—Myalgia—Methylprednisolone—ulcerative colitis	7.47e-05	0.000336	CcSEcCtD
Nilotinib—Eye disorder—Prednisone—ulcerative colitis	7.46e-05	0.000335	CcSEcCtD
Nilotinib—Anxiety—Methylprednisolone—ulcerative colitis	7.44e-05	0.000335	CcSEcCtD
Nilotinib—Tachycardia—Hydrocortisone—ulcerative colitis	7.44e-05	0.000334	CcSEcCtD
Nilotinib—Rash—Azathioprine—ulcerative colitis	7.42e-05	0.000334	CcSEcCtD
Nilotinib—Unspecified disorder of skin and subcutaneous tissue—Methylprednisolone—ulcerative colitis	7.42e-05	0.000334	CcSEcCtD
Nilotinib—Dermatitis—Azathioprine—ulcerative colitis	7.41e-05	0.000333	CcSEcCtD
Nilotinib—Flushing—Prednisone—ulcerative colitis	7.41e-05	0.000333	CcSEcCtD
Nilotinib—Skin disorder—Hydrocortisone—ulcerative colitis	7.4e-05	0.000333	CcSEcCtD
Nilotinib—Ill-defined disorder—Dexamethasone—ulcerative colitis	7.4e-05	0.000333	CcSEcCtD
Nilotinib—Ill-defined disorder—Betamethasone—ulcerative colitis	7.4e-05	0.000333	CcSEcCtD
Nilotinib—Discomfort—Triamcinolone—ulcerative colitis	7.4e-05	0.000333	CcSEcCtD
Nilotinib—Discomfort—Methylprednisolone—ulcerative colitis	7.38e-05	0.000332	CcSEcCtD
Nilotinib—Headache—Azathioprine—ulcerative colitis	7.37e-05	0.000331	CcSEcCtD
Nilotinib—Hyperhidrosis—Hydrocortisone—ulcerative colitis	7.37e-05	0.000331	CcSEcCtD
Nilotinib—Diarrhoea—Mesalazine—ulcerative colitis	7.33e-05	0.00033	CcSEcCtD
Nilotinib—Dry mouth—Triamcinolone—ulcerative colitis	7.32e-05	0.000329	CcSEcCtD
Nilotinib—Anorexia—Hydrocortisone—ulcerative colitis	7.27e-05	0.000327	CcSEcCtD
Nilotinib—Angiopathy—Prednisone—ulcerative colitis	7.24e-05	0.000326	CcSEcCtD
Nilotinib—Confusional state—Methylprednisolone—ulcerative colitis	7.22e-05	0.000325	CcSEcCtD
Nilotinib—Immune system disorder—Prednisone—ulcerative colitis	7.21e-05	0.000324	CcSEcCtD
Nilotinib—Malaise—Dexamethasone—ulcerative colitis	7.2e-05	0.000324	CcSEcCtD
Nilotinib—Malaise—Betamethasone—ulcerative colitis	7.2e-05	0.000324	CcSEcCtD
Nilotinib—Oedema—Triamcinolone—ulcerative colitis	7.18e-05	0.000323	CcSEcCtD
Nilotinib—Vertigo—Dexamethasone—ulcerative colitis	7.17e-05	0.000322	CcSEcCtD
Nilotinib—Vertigo—Betamethasone—ulcerative colitis	7.17e-05	0.000322	CcSEcCtD
Nilotinib—Syncope—Betamethasone—ulcerative colitis	7.16e-05	0.000322	CcSEcCtD
Nilotinib—Syncope—Dexamethasone—ulcerative colitis	7.16e-05	0.000322	CcSEcCtD
Nilotinib—Arrhythmia—Prednisone—ulcerative colitis	7.13e-05	0.000321	CcSEcCtD
Nilotinib—Infection—Triamcinolone—ulcerative colitis	7.13e-05	0.000321	CcSEcCtD
Nilotinib—Hypotension—Hydrocortisone—ulcerative colitis	7.12e-05	0.00032	CcSEcCtD
Nilotinib—Infection—Methylprednisolone—ulcerative colitis	7.11e-05	0.00032	CcSEcCtD
Nilotinib—Dizziness—Mesalazine—ulcerative colitis	7.09e-05	0.000319	CcSEcCtD
Nilotinib—Shock—Triamcinolone—ulcerative colitis	7.06e-05	0.000317	CcSEcCtD
Nilotinib—Insomnia—Prednisolone—ulcerative colitis	7.06e-05	0.000317	CcSEcCtD
Nilotinib—Alopecia—Prednisone—ulcerative colitis	7.05e-05	0.000317	CcSEcCtD
Nilotinib—Shock—Methylprednisolone—ulcerative colitis	7.05e-05	0.000317	CcSEcCtD
Nilotinib—Nervous system disorder—Methylprednisolone—ulcerative colitis	7.02e-05	0.000316	CcSEcCtD
Nilotinib—Loss of consciousness—Betamethasone—ulcerative colitis	7.01e-05	0.000315	CcSEcCtD
Nilotinib—Loss of consciousness—Dexamethasone—ulcerative colitis	7.01e-05	0.000315	CcSEcCtD
Nilotinib—Paraesthesia—Prednisolone—ulcerative colitis	7.01e-05	0.000315	CcSEcCtD
Nilotinib—Tachycardia—Triamcinolone—ulcerative colitis	7e-05	0.000315	CcSEcCtD
Nilotinib—Mental disorder—Prednisone—ulcerative colitis	6.99e-05	0.000314	CcSEcCtD
Nilotinib—Nausea—Azathioprine—ulcerative colitis	6.99e-05	0.000314	CcSEcCtD
Nilotinib—Tachycardia—Methylprednisolone—ulcerative colitis	6.99e-05	0.000314	CcSEcCtD
Nilotinib—Skin disorder—Methylprednisolone—ulcerative colitis	6.96e-05	0.000313	CcSEcCtD
Nilotinib—Erythema—Prednisone—ulcerative colitis	6.95e-05	0.000312	CcSEcCtD
Nilotinib—Malnutrition—Prednisone—ulcerative colitis	6.95e-05	0.000312	CcSEcCtD
Nilotinib—Musculoskeletal discomfort—Hydrocortisone—ulcerative colitis	6.94e-05	0.000312	CcSEcCtD
Nilotinib—Hyperhidrosis—Triamcinolone—ulcerative colitis	6.94e-05	0.000312	CcSEcCtD
Nilotinib—Hyperhidrosis—Methylprednisolone—ulcerative colitis	6.92e-05	0.000311	CcSEcCtD
Nilotinib—Insomnia—Hydrocortisone—ulcerative colitis	6.89e-05	0.00031	CcSEcCtD
Nilotinib—Hypertension—Dexamethasone—ulcerative colitis	6.89e-05	0.00031	CcSEcCtD
Nilotinib—Hypertension—Betamethasone—ulcerative colitis	6.89e-05	0.00031	CcSEcCtD
Nilotinib—Paraesthesia—Hydrocortisone—ulcerative colitis	6.84e-05	0.000308	CcSEcCtD
Nilotinib—Vomiting—Mesalazine—ulcerative colitis	6.82e-05	0.000306	CcSEcCtD
Nilotinib—Myalgia—Dexamethasone—ulcerative colitis	6.79e-05	0.000305	CcSEcCtD
Nilotinib—Myalgia—Betamethasone—ulcerative colitis	6.79e-05	0.000305	CcSEcCtD
Nilotinib—Anxiety—Betamethasone—ulcerative colitis	6.77e-05	0.000304	CcSEcCtD
Nilotinib—Anxiety—Dexamethasone—ulcerative colitis	6.77e-05	0.000304	CcSEcCtD
Nilotinib—Rash—Mesalazine—ulcerative colitis	6.76e-05	0.000304	CcSEcCtD
Nilotinib—Dermatitis—Mesalazine—ulcerative colitis	6.75e-05	0.000304	CcSEcCtD
Nilotinib—Headache—Mesalazine—ulcerative colitis	6.72e-05	0.000302	CcSEcCtD
Nilotinib—Discomfort—Betamethasone—ulcerative colitis	6.71e-05	0.000302	CcSEcCtD
Nilotinib—Discomfort—Dexamethasone—ulcerative colitis	6.71e-05	0.000302	CcSEcCtD
Nilotinib—Dyspepsia—Hydrocortisone—ulcerative colitis	6.71e-05	0.000302	CcSEcCtD
Nilotinib—Hypotension—Methylprednisolone—ulcerative colitis	6.69e-05	0.000301	CcSEcCtD
Nilotinib—Pain—Prednisolone—ulcerative colitis	6.67e-05	0.0003	CcSEcCtD
Nilotinib—Decreased appetite—Hydrocortisone—ulcerative colitis	6.63e-05	0.000298	CcSEcCtD
Nilotinib—Gastrointestinal disorder—Hydrocortisone—ulcerative colitis	6.58e-05	0.000296	CcSEcCtD
Nilotinib—Fatigue—Hydrocortisone—ulcerative colitis	6.57e-05	0.000295	CcSEcCtD
Nilotinib—Vision blurred—Prednisone—ulcerative colitis	6.55e-05	0.000294	CcSEcCtD
Nilotinib—Musculoskeletal discomfort—Triamcinolone—ulcerative colitis	6.54e-05	0.000294	CcSEcCtD
Nilotinib—Musculoskeletal discomfort—Methylprednisolone—ulcerative colitis	6.52e-05	0.000293	CcSEcCtD
Nilotinib—Pain—Hydrocortisone—ulcerative colitis	6.52e-05	0.000293	CcSEcCtD
Nilotinib—Oedema—Betamethasone—ulcerative colitis	6.51e-05	0.000293	CcSEcCtD
Nilotinib—Oedema—Dexamethasone—ulcerative colitis	6.51e-05	0.000293	CcSEcCtD
Nilotinib—Insomnia—Triamcinolone—ulcerative colitis	6.49e-05	0.000292	CcSEcCtD
Nilotinib—Insomnia—Methylprednisolone—ulcerative colitis	6.48e-05	0.000291	CcSEcCtD
Nilotinib—Infection—Dexamethasone—ulcerative colitis	6.47e-05	0.000291	CcSEcCtD
Nilotinib—Infection—Betamethasone—ulcerative colitis	6.47e-05	0.000291	CcSEcCtD
Nilotinib—Ill-defined disorder—Prednisone—ulcerative colitis	6.45e-05	0.00029	CcSEcCtD
Nilotinib—Paraesthesia—Triamcinolone—ulcerative colitis	6.44e-05	0.00029	CcSEcCtD
Nilotinib—Feeling abnormal—Prednisolone—ulcerative colitis	6.43e-05	0.000289	CcSEcCtD
Nilotinib—Paraesthesia—Methylprednisolone—ulcerative colitis	6.43e-05	0.000289	CcSEcCtD
Nilotinib—Anaemia—Prednisone—ulcerative colitis	6.42e-05	0.000289	CcSEcCtD
Nilotinib—Shock—Betamethasone—ulcerative colitis	6.41e-05	0.000288	CcSEcCtD
Nilotinib—Shock—Dexamethasone—ulcerative colitis	6.41e-05	0.000288	CcSEcCtD
Nilotinib—Dyspnoea—Triamcinolone—ulcerative colitis	6.4e-05	0.000288	CcSEcCtD
Nilotinib—Nervous system disorder—Dexamethasone—ulcerative colitis	6.39e-05	0.000287	CcSEcCtD
Nilotinib—Nervous system disorder—Betamethasone—ulcerative colitis	6.39e-05	0.000287	CcSEcCtD
Nilotinib—Thrombocytopenia—Betamethasone—ulcerative colitis	6.38e-05	0.000287	CcSEcCtD
Nilotinib—Thrombocytopenia—Dexamethasone—ulcerative colitis	6.38e-05	0.000287	CcSEcCtD
Nilotinib—Nausea—Mesalazine—ulcerative colitis	6.37e-05	0.000286	CcSEcCtD
Nilotinib—Tachycardia—Betamethasone—ulcerative colitis	6.36e-05	0.000286	CcSEcCtD
Nilotinib—Tachycardia—Dexamethasone—ulcerative colitis	6.36e-05	0.000286	CcSEcCtD
Nilotinib—Dyspepsia—Triamcinolone—ulcerative colitis	6.32e-05	0.000284	CcSEcCtD
Nilotinib—Dyspepsia—Methylprednisolone—ulcerative colitis	6.3e-05	0.000283	CcSEcCtD
Nilotinib—Hyperhidrosis—Betamethasone—ulcerative colitis	6.3e-05	0.000283	CcSEcCtD
Nilotinib—Hyperhidrosis—Dexamethasone—ulcerative colitis	6.3e-05	0.000283	CcSEcCtD
Nilotinib—Feeling abnormal—Hydrocortisone—ulcerative colitis	6.28e-05	0.000282	CcSEcCtD
Nilotinib—Malaise—Prednisone—ulcerative colitis	6.27e-05	0.000282	CcSEcCtD
Nilotinib—Vertigo—Prednisone—ulcerative colitis	6.24e-05	0.000281	CcSEcCtD
Nilotinib—Gastrointestinal pain—Hydrocortisone—ulcerative colitis	6.23e-05	0.00028	CcSEcCtD
Nilotinib—Syncope—Prednisone—ulcerative colitis	6.23e-05	0.00028	CcSEcCtD
Nilotinib—Anorexia—Dexamethasone—ulcerative colitis	6.21e-05	0.000279	CcSEcCtD
Nilotinib—Anorexia—Betamethasone—ulcerative colitis	6.21e-05	0.000279	CcSEcCtD
Nilotinib—Urticaria—Prednisolone—ulcerative colitis	6.2e-05	0.000279	CcSEcCtD
Nilotinib—Fatigue—Triamcinolone—ulcerative colitis	6.19e-05	0.000278	CcSEcCtD
Nilotinib—Fatigue—Methylprednisolone—ulcerative colitis	6.17e-05	0.000278	CcSEcCtD
Nilotinib—Pain—Triamcinolone—ulcerative colitis	6.14e-05	0.000276	CcSEcCtD
Nilotinib—Loss of consciousness—Prednisone—ulcerative colitis	6.11e-05	0.000275	CcSEcCtD
Nilotinib—Hypotension—Betamethasone—ulcerative colitis	6.09e-05	0.000274	CcSEcCtD
Nilotinib—Hypotension—Dexamethasone—ulcerative colitis	6.09e-05	0.000274	CcSEcCtD
Nilotinib—Urticaria—Hydrocortisone—ulcerative colitis	6.06e-05	0.000272	CcSEcCtD
Nilotinib—Body temperature increased—Hydrocortisone—ulcerative colitis	6.03e-05	0.000271	CcSEcCtD
Nilotinib—Abdominal pain—Hydrocortisone—ulcerative colitis	6.03e-05	0.000271	CcSEcCtD
Nilotinib—Hypertension—Prednisone—ulcerative colitis	6e-05	0.00027	CcSEcCtD
Nilotinib—Musculoskeletal discomfort—Betamethasone—ulcerative colitis	5.93e-05	0.000267	CcSEcCtD
Nilotinib—Musculoskeletal discomfort—Dexamethasone—ulcerative colitis	5.93e-05	0.000267	CcSEcCtD
Nilotinib—Myalgia—Prednisone—ulcerative colitis	5.92e-05	0.000266	CcSEcCtD
Nilotinib—Arthralgia—Prednisone—ulcerative colitis	5.92e-05	0.000266	CcSEcCtD
Nilotinib—Feeling abnormal—Triamcinolone—ulcerative colitis	5.91e-05	0.000266	CcSEcCtD
Nilotinib—Feeling abnormal—Methylprednisolone—ulcerative colitis	5.9e-05	0.000265	CcSEcCtD
Nilotinib—Anxiety—Prednisone—ulcerative colitis	5.9e-05	0.000265	CcSEcCtD
Nilotinib—Insomnia—Betamethasone—ulcerative colitis	5.89e-05	0.000265	CcSEcCtD
Nilotinib—Insomnia—Dexamethasone—ulcerative colitis	5.89e-05	0.000265	CcSEcCtD
Nilotinib—Unspecified disorder of skin and subcutaneous tissue—Prednisone—ulcerative colitis	5.88e-05	0.000264	CcSEcCtD
Nilotinib—Gastrointestinal pain—Methylprednisolone—ulcerative colitis	5.86e-05	0.000263	CcSEcCtD
Nilotinib—Paraesthesia—Dexamethasone—ulcerative colitis	5.85e-05	0.000263	CcSEcCtD
Nilotinib—Paraesthesia—Betamethasone—ulcerative colitis	5.85e-05	0.000263	CcSEcCtD
Nilotinib—Discomfort—Prednisone—ulcerative colitis	5.85e-05	0.000263	CcSEcCtD
Nilotinib—Hypersensitivity—Prednisolone—ulcerative colitis	5.75e-05	0.000259	CcSEcCtD
Nilotinib—Dyspepsia—Dexamethasone—ulcerative colitis	5.73e-05	0.000258	CcSEcCtD
Nilotinib—Dyspepsia—Betamethasone—ulcerative colitis	5.73e-05	0.000258	CcSEcCtD
Nilotinib—Urticaria—Triamcinolone—ulcerative colitis	5.7e-05	0.000256	CcSEcCtD
Nilotinib—Urticaria—Methylprednisolone—ulcerative colitis	5.69e-05	0.000256	CcSEcCtD
Nilotinib—Body temperature increased—Triamcinolone—ulcerative colitis	5.67e-05	0.000255	CcSEcCtD
Nilotinib—Oedema—Prednisone—ulcerative colitis	5.67e-05	0.000255	CcSEcCtD
Nilotinib—Abdominal pain—Methylprednisolone—ulcerative colitis	5.66e-05	0.000255	CcSEcCtD
Nilotinib—Decreased appetite—Dexamethasone—ulcerative colitis	5.66e-05	0.000255	CcSEcCtD
Nilotinib—Decreased appetite—Betamethasone—ulcerative colitis	5.66e-05	0.000255	CcSEcCtD
Nilotinib—Infection—Prednisone—ulcerative colitis	5.63e-05	0.000253	CcSEcCtD
Nilotinib—Gastrointestinal disorder—Betamethasone—ulcerative colitis	5.62e-05	0.000253	CcSEcCtD
Nilotinib—Gastrointestinal disorder—Dexamethasone—ulcerative colitis	5.62e-05	0.000253	CcSEcCtD
Nilotinib—Hypersensitivity—Hydrocortisone—ulcerative colitis	5.62e-05	0.000252	CcSEcCtD
Nilotinib—Fatigue—Dexamethasone—ulcerative colitis	5.61e-05	0.000252	CcSEcCtD
Nilotinib—Fatigue—Betamethasone—ulcerative colitis	5.61e-05	0.000252	CcSEcCtD
Nilotinib—Shock—Prednisone—ulcerative colitis	5.58e-05	0.000251	CcSEcCtD
Nilotinib—Pain—Dexamethasone—ulcerative colitis	5.57e-05	0.00025	CcSEcCtD
Nilotinib—Pain—Betamethasone—ulcerative colitis	5.57e-05	0.00025	CcSEcCtD
Nilotinib—Nervous system disorder—Prednisone—ulcerative colitis	5.56e-05	0.00025	CcSEcCtD
Nilotinib—Tachycardia—Prednisone—ulcerative colitis	5.54e-05	0.000249	CcSEcCtD
Nilotinib—Skin disorder—Prednisone—ulcerative colitis	5.51e-05	0.000248	CcSEcCtD
Nilotinib—Hyperhidrosis—Prednisone—ulcerative colitis	5.48e-05	0.000246	CcSEcCtD
Nilotinib—Asthenia—Hydrocortisone—ulcerative colitis	5.47e-05	0.000246	CcSEcCtD
Nilotinib—Anorexia—Prednisone—ulcerative colitis	5.41e-05	0.000243	CcSEcCtD
Nilotinib—Pruritus—Hydrocortisone—ulcerative colitis	5.39e-05	0.000242	CcSEcCtD
Nilotinib—Feeling abnormal—Betamethasone—ulcerative colitis	5.37e-05	0.000241	CcSEcCtD
Nilotinib—Feeling abnormal—Dexamethasone—ulcerative colitis	5.37e-05	0.000241	CcSEcCtD
Nilotinib—Gastrointestinal pain—Betamethasone—ulcerative colitis	5.33e-05	0.000239	CcSEcCtD
Nilotinib—Gastrointestinal pain—Dexamethasone—ulcerative colitis	5.33e-05	0.000239	CcSEcCtD
Nilotinib—Hypersensitivity—Triamcinolone—ulcerative colitis	5.29e-05	0.000238	CcSEcCtD
Nilotinib—Hypersensitivity—Methylprednisolone—ulcerative colitis	5.28e-05	0.000237	CcSEcCtD
Nilotinib—Diarrhoea—Hydrocortisone—ulcerative colitis	5.22e-05	0.000234	CcSEcCtD
Nilotinib—Urticaria—Betamethasone—ulcerative colitis	5.17e-05	0.000233	CcSEcCtD
Nilotinib—Urticaria—Dexamethasone—ulcerative colitis	5.17e-05	0.000233	CcSEcCtD
Nilotinib—Musculoskeletal discomfort—Prednisone—ulcerative colitis	5.17e-05	0.000232	CcSEcCtD
Nilotinib—Dizziness—Prednisolone—ulcerative colitis	5.16e-05	0.000232	CcSEcCtD
Nilotinib—Asthenia—Triamcinolone—ulcerative colitis	5.15e-05	0.000232	CcSEcCtD
Nilotinib—Abdominal pain—Dexamethasone—ulcerative colitis	5.15e-05	0.000231	CcSEcCtD
Nilotinib—Body temperature increased—Betamethasone—ulcerative colitis	5.15e-05	0.000231	CcSEcCtD
Nilotinib—Abdominal pain—Betamethasone—ulcerative colitis	5.15e-05	0.000231	CcSEcCtD
Nilotinib—Body temperature increased—Dexamethasone—ulcerative colitis	5.15e-05	0.000231	CcSEcCtD
Nilotinib—Asthenia—Methylprednisolone—ulcerative colitis	5.14e-05	0.000231	CcSEcCtD
Nilotinib—Insomnia—Prednisone—ulcerative colitis	5.13e-05	0.000231	CcSEcCtD
Nilotinib—Paraesthesia—Prednisone—ulcerative colitis	5.09e-05	0.000229	CcSEcCtD
Nilotinib—Pruritus—Triamcinolone—ulcerative colitis	5.08e-05	0.000228	CcSEcCtD
Nilotinib—Pruritus—Methylprednisolone—ulcerative colitis	5.07e-05	0.000228	CcSEcCtD
Nilotinib—Dizziness—Hydrocortisone—ulcerative colitis	5.04e-05	0.000227	CcSEcCtD
Nilotinib—Dyspepsia—Prednisone—ulcerative colitis	4.99e-05	0.000224	CcSEcCtD
Nilotinib—Decreased appetite—Prednisone—ulcerative colitis	4.93e-05	0.000222	CcSEcCtD
Nilotinib—Rash—Prednisolone—ulcerative colitis	4.92e-05	0.000221	CcSEcCtD
Nilotinib—Dermatitis—Prednisolone—ulcerative colitis	4.92e-05	0.000221	CcSEcCtD
Nilotinib—Diarrhoea—Methylprednisolone—ulcerative colitis	4.9e-05	0.00022	CcSEcCtD
Nilotinib—Fatigue—Prednisone—ulcerative colitis	4.89e-05	0.00022	CcSEcCtD
Nilotinib—Headache—Prednisolone—ulcerative colitis	4.89e-05	0.00022	CcSEcCtD
Nilotinib—Constipation—Prednisone—ulcerative colitis	4.85e-05	0.000218	CcSEcCtD
Nilotinib—Vomiting—Hydrocortisone—ulcerative colitis	4.85e-05	0.000218	CcSEcCtD
Nilotinib—Rash—Hydrocortisone—ulcerative colitis	4.81e-05	0.000216	CcSEcCtD
Nilotinib—Dermatitis—Hydrocortisone—ulcerative colitis	4.8e-05	0.000216	CcSEcCtD
Nilotinib—Headache—Hydrocortisone—ulcerative colitis	4.78e-05	0.000215	CcSEcCtD
Nilotinib—Dizziness—Triamcinolone—ulcerative colitis	4.75e-05	0.000213	CcSEcCtD
Nilotinib—Dizziness—Methylprednisolone—ulcerative colitis	4.74e-05	0.000213	CcSEcCtD
Nilotinib—Feeling abnormal—Prednisone—ulcerative colitis	4.67e-05	0.00021	CcSEcCtD
Nilotinib—Asthenia—Dexamethasone—ulcerative colitis	4.67e-05	0.00021	CcSEcCtD
Nilotinib—Asthenia—Betamethasone—ulcerative colitis	4.67e-05	0.00021	CcSEcCtD
Nilotinib—Gastrointestinal pain—Prednisone—ulcerative colitis	4.64e-05	0.000208	CcSEcCtD
Nilotinib—Nausea—Prednisolone—ulcerative colitis	4.64e-05	0.000208	CcSEcCtD
Nilotinib—Pruritus—Dexamethasone—ulcerative colitis	4.61e-05	0.000207	CcSEcCtD
Nilotinib—Pruritus—Betamethasone—ulcerative colitis	4.61e-05	0.000207	CcSEcCtD
Nilotinib—Vomiting—Triamcinolone—ulcerative colitis	4.56e-05	0.000205	CcSEcCtD
Nilotinib—Vomiting—Methylprednisolone—ulcerative colitis	4.55e-05	0.000205	CcSEcCtD
Nilotinib—Nausea—Hydrocortisone—ulcerative colitis	4.53e-05	0.000204	CcSEcCtD
Nilotinib—Rash—Triamcinolone—ulcerative colitis	4.53e-05	0.000203	CcSEcCtD
Nilotinib—Dermatitis—Triamcinolone—ulcerative colitis	4.52e-05	0.000203	CcSEcCtD
Nilotinib—Rash—Methylprednisolone—ulcerative colitis	4.52e-05	0.000203	CcSEcCtD
Nilotinib—Dermatitis—Methylprednisolone—ulcerative colitis	4.51e-05	0.000203	CcSEcCtD
Nilotinib—Urticaria—Prednisone—ulcerative colitis	4.51e-05	0.000203	CcSEcCtD
Nilotinib—Headache—Triamcinolone—ulcerative colitis	4.5e-05	0.000202	CcSEcCtD
Nilotinib—Headache—Methylprednisolone—ulcerative colitis	4.49e-05	0.000202	CcSEcCtD
Nilotinib—Abdominal pain—Prednisone—ulcerative colitis	4.48e-05	0.000202	CcSEcCtD
Nilotinib—Body temperature increased—Prednisone—ulcerative colitis	4.48e-05	0.000202	CcSEcCtD
Nilotinib—Diarrhoea—Dexamethasone—ulcerative colitis	4.46e-05	0.0002	CcSEcCtD
Nilotinib—Diarrhoea—Betamethasone—ulcerative colitis	4.46e-05	0.0002	CcSEcCtD
Nilotinib—Dizziness—Betamethasone—ulcerative colitis	4.31e-05	0.000194	CcSEcCtD
Nilotinib—Dizziness—Dexamethasone—ulcerative colitis	4.31e-05	0.000194	CcSEcCtD
Nilotinib—Nausea—Triamcinolone—ulcerative colitis	4.26e-05	0.000192	CcSEcCtD
Nilotinib—Nausea—Methylprednisolone—ulcerative colitis	4.25e-05	0.000191	CcSEcCtD
Nilotinib—Hypersensitivity—Prednisone—ulcerative colitis	4.18e-05	0.000188	CcSEcCtD
Nilotinib—Vomiting—Dexamethasone—ulcerative colitis	4.14e-05	0.000186	CcSEcCtD
Nilotinib—Vomiting—Betamethasone—ulcerative colitis	4.14e-05	0.000186	CcSEcCtD
Nilotinib—Rash—Dexamethasone—ulcerative colitis	4.11e-05	0.000185	CcSEcCtD
Nilotinib—Rash—Betamethasone—ulcerative colitis	4.11e-05	0.000185	CcSEcCtD
Nilotinib—Dermatitis—Dexamethasone—ulcerative colitis	4.1e-05	0.000184	CcSEcCtD
Nilotinib—Dermatitis—Betamethasone—ulcerative colitis	4.1e-05	0.000184	CcSEcCtD
Nilotinib—Headache—Dexamethasone—ulcerative colitis	4.08e-05	0.000183	CcSEcCtD
Nilotinib—Headache—Betamethasone—ulcerative colitis	4.08e-05	0.000183	CcSEcCtD
Nilotinib—Asthenia—Prednisone—ulcerative colitis	4.07e-05	0.000183	CcSEcCtD
Nilotinib—Pruritus—Prednisone—ulcerative colitis	4.01e-05	0.00018	CcSEcCtD
Nilotinib—Diarrhoea—Prednisone—ulcerative colitis	3.88e-05	0.000174	CcSEcCtD
Nilotinib—Nausea—Betamethasone—ulcerative colitis	3.87e-05	0.000174	CcSEcCtD
Nilotinib—Nausea—Dexamethasone—ulcerative colitis	3.87e-05	0.000174	CcSEcCtD
Nilotinib—Dizziness—Prednisone—ulcerative colitis	3.75e-05	0.000169	CcSEcCtD
Nilotinib—Vomiting—Prednisone—ulcerative colitis	3.61e-05	0.000162	CcSEcCtD
Nilotinib—Rash—Prednisone—ulcerative colitis	3.58e-05	0.000161	CcSEcCtD
Nilotinib—Dermatitis—Prednisone—ulcerative colitis	3.57e-05	0.000161	CcSEcCtD
Nilotinib—Headache—Prednisone—ulcerative colitis	3.55e-05	0.00016	CcSEcCtD
Nilotinib—Nausea—Prednisone—ulcerative colitis	3.37e-05	0.000151	CcSEcCtD
Nilotinib—CYP2C8—Metabolism of lipids and lipoproteins—PPARG—ulcerative colitis	5e-06	2.36e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Immune System—JAK2—ulcerative colitis	4.99e-06	2.35e-05	CbGpPWpGaD
Nilotinib—MAPK14—Hemostasis—TP53—ulcerative colitis	4.95e-06	2.33e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Immune System—IFNG—ulcerative colitis	4.9e-06	2.31e-05	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—ADRB2—ulcerative colitis	4.89e-06	2.31e-05	CbGpPWpGaD
Nilotinib—LYN—Immune System—JAK2—ulcerative colitis	4.89e-06	2.3e-05	CbGpPWpGaD
Nilotinib—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—ulcerative colitis	4.89e-06	2.3e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Innate Immune System—IL6—ulcerative colitis	4.88e-06	2.3e-05	CbGpPWpGaD
Nilotinib—LYN—Developmental Biology—IL6—ulcerative colitis	4.87e-06	2.29e-05	CbGpPWpGaD
Nilotinib—ABL1—Immune System—JAK2—ulcerative colitis	4.87e-06	2.29e-05	CbGpPWpGaD
Nilotinib—CYP2B6—Metabolism—CALM3—ulcerative colitis	4.86e-06	2.29e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Immune System—IL1B—ulcerative colitis	4.85e-06	2.28e-05	CbGpPWpGaD
Nilotinib—MAP2K5—Signaling Pathways—RELA—ulcerative colitis	4.85e-06	2.28e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Disease—CD4—ulcerative colitis	4.85e-06	2.28e-05	CbGpPWpGaD
Nilotinib—ABL1—Developmental Biology—IL6—ulcerative colitis	4.85e-06	2.28e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Immune System—RELA—ulcerative colitis	4.83e-06	2.28e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Immune System—IL2—ulcerative colitis	4.83e-06	2.28e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Disease—PTGS2—ulcerative colitis	4.81e-06	2.27e-05	CbGpPWpGaD
Nilotinib—ABCG2—Metabolism—ADCY5—ulcerative colitis	4.81e-06	2.27e-05	CbGpPWpGaD
Nilotinib—MAPK8—Signaling Pathways—CXCL8—ulcerative colitis	4.81e-06	2.26e-05	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—ADCY5—ulcerative colitis	4.81e-06	2.26e-05	CbGpPWpGaD
Nilotinib—LYN—Immune System—IFNG—ulcerative colitis	4.8e-06	2.26e-05	CbGpPWpGaD
Nilotinib—KIT—Immune System—NFKB1—ulcerative colitis	4.78e-06	2.25e-05	CbGpPWpGaD
Nilotinib—ABL1—Immune System—IFNG—ulcerative colitis	4.78e-06	2.25e-05	CbGpPWpGaD
Nilotinib—MAPK11—Immune System—STAT3—ulcerative colitis	4.77e-06	2.24e-05	CbGpPWpGaD
Nilotinib—LYN—Immune System—RELA—ulcerative colitis	4.73e-06	2.23e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Immune System—CD4—ulcerative colitis	4.73e-06	2.23e-05	CbGpPWpGaD
Nilotinib—ABL1—Immune System—RELA—ulcerative colitis	4.71e-06	2.22e-05	CbGpPWpGaD
Nilotinib—MAPK14—Immune System—JAK2—ulcerative colitis	4.63e-06	2.18e-05	CbGpPWpGaD
Nilotinib—LYN—Immune System—CD4—ulcerative colitis	4.63e-06	2.18e-05	CbGpPWpGaD
Nilotinib—MAPK14—Developmental Biology—IL6—ulcerative colitis	4.62e-06	2.17e-05	CbGpPWpGaD
Nilotinib—ABL1—Immune System—CD4—ulcerative colitis	4.61e-06	2.17e-05	CbGpPWpGaD
Nilotinib—HCK—Immune System—IL6—ulcerative colitis	4.61e-06	2.17e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Disease—JAK2—ulcerative colitis	4.61e-06	2.17e-05	CbGpPWpGaD
Nilotinib—MAPK8—Signaling Pathways—IL2—ulcerative colitis	4.6e-06	2.16e-05	CbGpPWpGaD
Nilotinib—CYP2C8—Metabolism—PTGS1—ulcerative colitis	4.57e-06	2.15e-05	CbGpPWpGaD
Nilotinib—MAP2K5—Signaling Pathways—CXCL8—ulcerative colitis	4.57e-06	2.15e-05	CbGpPWpGaD
Nilotinib—LCK—Immune System—CDH1—ulcerative colitis	4.57e-06	2.15e-05	CbGpPWpGaD
Nilotinib—MAPK14—Immune System—IFNG—ulcerative colitis	4.55e-06	2.14e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Immune System—NFKB1—ulcerative colitis	4.53e-06	2.13e-05	CbGpPWpGaD
Nilotinib—CYP2C8—Metabolism of lipids and lipoproteins—ALB—ulcerative colitis	4.5e-06	2.12e-05	CbGpPWpGaD
Nilotinib—MAPK14—Immune System—RELA—ulcerative colitis	4.49e-06	2.11e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Innate Immune System—IL6—ulcerative colitis	4.39e-06	2.07e-05	CbGpPWpGaD
Nilotinib—MAPK14—Immune System—CD4—ulcerative colitis	4.39e-06	2.07e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Immune System—IL1B—ulcerative colitis	4.37e-06	2.06e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Disease—CD4—ulcerative colitis	4.37e-06	2.06e-05	CbGpPWpGaD
Nilotinib—MAP2K5—Signaling Pathways—IL2—ulcerative colitis	4.37e-06	2.06e-05	CbGpPWpGaD
Nilotinib—BRAF—Disease—STAT3—ulcerative colitis	4.36e-06	2.05e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Immune System—IL2—ulcerative colitis	4.35e-06	2.05e-05	CbGpPWpGaD
Nilotinib—MAPK8—Signaling Pathways—MMP9—ulcerative colitis	4.35e-06	2.05e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Disease—PTGS2—ulcerative colitis	4.34e-06	2.04e-05	CbGpPWpGaD
Nilotinib—MAPK8—Signaling Pathways—NFKB1—ulcerative colitis	4.3e-06	2.03e-05	CbGpPWpGaD
Nilotinib—LYN—Innate Immune System—IL6—ulcerative colitis	4.3e-06	2.03e-05	CbGpPWpGaD
Nilotinib—KIT—Immune System—STAT3—ulcerative colitis	4.3e-06	2.02e-05	CbGpPWpGaD
Nilotinib—ABL1—Innate Immune System—IL6—ulcerative colitis	4.28e-06	2.02e-05	CbGpPWpGaD
Nilotinib—LCK—Hemostasis—TP53—ulcerative colitis	4.28e-06	2.02e-05	CbGpPWpGaD
Nilotinib—LYN—Immune System—IL1B—ulcerative colitis	4.28e-06	2.02e-05	CbGpPWpGaD
Nilotinib—LYN—Immune System—IL2—ulcerative colitis	4.26e-06	2.01e-05	CbGpPWpGaD
Nilotinib—ABL1—Immune System—IL1B—ulcerative colitis	4.26e-06	2.01e-05	CbGpPWpGaD
Nilotinib—HCK—Disease—IL6—ulcerative colitis	4.26e-06	2e-05	CbGpPWpGaD
Nilotinib—ABL1—Immune System—IL2—ulcerative colitis	4.24e-06	2e-05	CbGpPWpGaD
Nilotinib—UGT1A1—Metabolism—PPARG—ulcerative colitis	4.23e-06	1.99e-05	CbGpPWpGaD
Nilotinib—MAPK11—Signaling Pathways—JAK2—ulcerative colitis	4.2e-06	1.98e-05	CbGpPWpGaD
Nilotinib—MAPK8—Immune System—IL6—ulcerative colitis	4.18e-06	1.97e-05	CbGpPWpGaD
Nilotinib—BLK—Immune System—IL6—ulcerative colitis	4.18e-06	1.97e-05	CbGpPWpGaD
Nilotinib—FGR—Immune System—IL6—ulcerative colitis	4.16e-06	1.96e-05	CbGpPWpGaD
Nilotinib—BRAF—Signaling Pathways—JAK2—ulcerative colitis	4.16e-06	1.96e-05	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—ADCY5—ulcerative colitis	4.15e-06	1.96e-05	CbGpPWpGaD
Nilotinib—MAP2K5—Signaling Pathways—MMP9—ulcerative colitis	4.13e-06	1.95e-05	CbGpPWpGaD
Nilotinib—CYP2C8—Metabolism—CALM3—ulcerative colitis	4.12e-06	1.94e-05	CbGpPWpGaD
Nilotinib—MAP2K5—Signaling Pathways—NFKB1—ulcerative colitis	4.09e-06	1.93e-05	CbGpPWpGaD
Nilotinib—MAPK14—Innate Immune System—IL6—ulcerative colitis	4.08e-06	1.92e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Immune System—NFKB1—ulcerative colitis	4.08e-06	1.92e-05	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism of lipids and lipoproteins—PPARG—ulcerative colitis	4.07e-06	1.92e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Immune System—STAT3—ulcerative colitis	4.07e-06	1.92e-05	CbGpPWpGaD
Nilotinib—MAPK11—Signaling Pathways—RELA—ulcerative colitis	4.07e-06	1.91e-05	CbGpPWpGaD
Nilotinib—MAPK14—Immune System—IL1B—ulcerative colitis	4.06e-06	1.91e-05	CbGpPWpGaD
Nilotinib—MAPK14—Immune System—IL2—ulcerative colitis	4.04e-06	1.9e-05	CbGpPWpGaD
Nilotinib—BRAF—Disease—TGFB1—ulcerative colitis	4.04e-06	1.9e-05	CbGpPWpGaD
Nilotinib—BRAF—Signaling Pathways—RELA—ulcerative colitis	4.03e-06	1.9e-05	CbGpPWpGaD
Nilotinib—LCK—Immune System—JAK2—ulcerative colitis	4.01e-06	1.89e-05	CbGpPWpGaD
Nilotinib—LYN—Immune System—NFKB1—ulcerative colitis	3.99e-06	1.88e-05	CbGpPWpGaD
Nilotinib—ABCB1—Metabolism—PTGS1—ulcerative colitis	3.98e-06	1.88e-05	CbGpPWpGaD
Nilotinib—ABL1—Immune System—NFKB1—ulcerative colitis	3.97e-06	1.87e-05	CbGpPWpGaD
Nilotinib—KIT—Disease—STAT3—ulcerative colitis	3.97e-06	1.87e-05	CbGpPWpGaD
Nilotinib—CYP2C8—Metabolism of lipids and lipoproteins—PTGS2—ulcerative colitis	3.94e-06	1.85e-05	CbGpPWpGaD
Nilotinib—LCK—Immune System—IFNG—ulcerative colitis	3.93e-06	1.85e-05	CbGpPWpGaD
Nilotinib—LCK—Immune System—RELA—ulcerative colitis	3.88e-06	1.83e-05	CbGpPWpGaD
Nilotinib—MAPK8—Signaling Pathways—STAT3—ulcerative colitis	3.87e-06	1.82e-05	CbGpPWpGaD
Nilotinib—MAPK11—Signaling Pathways—CXCL8—ulcerative colitis	3.83e-06	1.8e-05	CbGpPWpGaD
Nilotinib—UGT1A1—Metabolism—ALB—ulcerative colitis	3.8e-06	1.79e-05	CbGpPWpGaD
Nilotinib—LCK—Immune System—CD4—ulcerative colitis	3.8e-06	1.79e-05	CbGpPWpGaD
Nilotinib—BRAF—Signaling Pathways—CXCL8—ulcerative colitis	3.8e-06	1.79e-05	CbGpPWpGaD
Nilotinib—KIT—Signaling Pathways—JAK2—ulcerative colitis	3.78e-06	1.78e-05	CbGpPWpGaD
Nilotinib—MAPK14—Immune System—NFKB1—ulcerative colitis	3.78e-06	1.78e-05	CbGpPWpGaD
Nilotinib—CYP2B6—Metabolism—ABCB1—ulcerative colitis	3.78e-06	1.78e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Disease—STAT3—ulcerative colitis	3.76e-06	1.77e-05	CbGpPWpGaD
Nilotinib—CYP2D6—Metabolism—PTGS1—ulcerative colitis	3.75e-06	1.77e-05	CbGpPWpGaD
Nilotinib—ABCB1—Transmembrane transport of small molecules—ALB—ulcerative colitis	3.73e-06	1.75e-05	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism—PTGS1—ulcerative colitis	3.72e-06	1.75e-05	CbGpPWpGaD
Nilotinib—LCK—Disease—JAK2—ulcerative colitis	3.7e-06	1.74e-05	CbGpPWpGaD
Nilotinib—KIT—Disease—TGFB1—ulcerative colitis	3.68e-06	1.73e-05	CbGpPWpGaD
Nilotinib—MAP2K5—Signaling Pathways—STAT3—ulcerative colitis	3.68e-06	1.73e-05	CbGpPWpGaD
Nilotinib—KIT—Signaling Pathways—RELA—ulcerative colitis	3.67e-06	1.73e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Immune System—STAT3—ulcerative colitis	3.66e-06	1.73e-05	CbGpPWpGaD
Nilotinib—MAPK11—Signaling Pathways—IL2—ulcerative colitis	3.66e-06	1.72e-05	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism of lipids and lipoproteins—ALB—ulcerative colitis	3.66e-06	1.72e-05	CbGpPWpGaD
Nilotinib—BRAF—Signaling Pathways—IL2—ulcerative colitis	3.63e-06	1.71e-05	CbGpPWpGaD
Nilotinib—ABCG2—Metabolism—PPARG—ulcerative colitis	3.59e-06	1.69e-05	CbGpPWpGaD
Nilotinib—LYN—Immune System—STAT3—ulcerative colitis	3.59e-06	1.69e-05	CbGpPWpGaD
Nilotinib—ABCB1—Metabolism—CALM3—ulcerative colitis	3.59e-06	1.69e-05	CbGpPWpGaD
Nilotinib—MAPK8—Signaling Pathways—TGFB1—ulcerative colitis	3.58e-06	1.69e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—JAK2—ulcerative colitis	3.58e-06	1.69e-05	CbGpPWpGaD
Nilotinib—ABL1—Immune System—STAT3—ulcerative colitis	3.57e-06	1.68e-05	CbGpPWpGaD
Nilotinib—CYP2B6—Metabolism—ADCY5—ulcerative colitis	3.53e-06	1.66e-05	CbGpPWpGaD
Nilotinib—LCK—Innate Immune System—IL6—ulcerative colitis	3.53e-06	1.66e-05	CbGpPWpGaD
Nilotinib—LCK—Immune System—IL1B—ulcerative colitis	3.51e-06	1.65e-05	CbGpPWpGaD
Nilotinib—LCK—Disease—CD4—ulcerative colitis	3.51e-06	1.65e-05	CbGpPWpGaD
Nilotinib—LCK—Immune System—IL2—ulcerative colitis	3.49e-06	1.65e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Disease—TGFB1—ulcerative colitis	3.48e-06	1.64e-05	CbGpPWpGaD
Nilotinib—LCK—Disease—PTGS2—ulcerative colitis	3.48e-06	1.64e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—RELA—ulcerative colitis	3.47e-06	1.63e-05	CbGpPWpGaD
Nilotinib—MAPK11—Signaling Pathways—MMP9—ulcerative colitis	3.47e-06	1.63e-05	CbGpPWpGaD
Nilotinib—KIT—Signaling Pathways—CXCL8—ulcerative colitis	3.45e-06	1.63e-05	CbGpPWpGaD
Nilotinib—BRAF—Signaling Pathways—MMP9—ulcerative colitis	3.43e-06	1.62e-05	CbGpPWpGaD
Nilotinib—MAPK11—Signaling Pathways—NFKB1—ulcerative colitis	3.43e-06	1.61e-05	CbGpPWpGaD
Nilotinib—MAP2K5—Signaling Pathways—TGFB1—ulcerative colitis	3.41e-06	1.6e-05	CbGpPWpGaD
Nilotinib—MAPK14—Immune System—STAT3—ulcerative colitis	3.4e-06	1.6e-05	CbGpPWpGaD
Nilotinib—BRAF—Signaling Pathways—NFKB1—ulcerative colitis	3.4e-06	1.6e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Disease—STAT3—ulcerative colitis	3.38e-06	1.59e-05	CbGpPWpGaD
Nilotinib—CYP2D6—Metabolism—CALM3—ulcerative colitis	3.38e-06	1.59e-05	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism—CALM3—ulcerative colitis	3.35e-06	1.58e-05	CbGpPWpGaD
Nilotinib—MAPK11—Immune System—IL6—ulcerative colitis	3.33e-06	1.57e-05	CbGpPWpGaD
Nilotinib—UGT1A1—Metabolism—PTGS2—ulcerative colitis	3.33e-06	1.57e-05	CbGpPWpGaD
Nilotinib—KIT—Signaling Pathways—IL2—ulcerative colitis	3.3e-06	1.55e-05	CbGpPWpGaD
Nilotinib—LCK—Immune System—NFKB1—ulcerative colitis	3.27e-06	1.54e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—CXCL8—ulcerative colitis	3.27e-06	1.54e-05	CbGpPWpGaD
Nilotinib—ABCG2—Metabolism—ALB—ulcerative colitis	3.23e-06	1.52e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—JAK2—ulcerative colitis	3.23e-06	1.52e-05	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—ulcerative colitis	3.2e-06	1.51e-05	CbGpPWpGaD
Nilotinib—CYP2C8—Metabolism—ABCB1—ulcerative colitis	3.2e-06	1.51e-05	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—JAK2—ulcerative colitis	3.16e-06	1.49e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Disease—TGFB1—ulcerative colitis	3.14e-06	1.48e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—RELA—ulcerative colitis	3.13e-06	1.47e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—IL2—ulcerative colitis	3.12e-06	1.47e-05	CbGpPWpGaD
Nilotinib—KIT—Signaling Pathways—MMP9—ulcerative colitis	3.12e-06	1.47e-05	CbGpPWpGaD
Nilotinib—KIT—Signaling Pathways—NFKB1—ulcerative colitis	3.09e-06	1.46e-05	CbGpPWpGaD
Nilotinib—MAPK11—Signaling Pathways—STAT3—ulcerative colitis	3.08e-06	1.45e-05	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—RELA—ulcerative colitis	3.06e-06	1.44e-05	CbGpPWpGaD
Nilotinib—BRAF—Signaling Pathways—STAT3—ulcerative colitis	3.05e-06	1.44e-05	CbGpPWpGaD
Nilotinib—BRAF—Disease—IL6—ulcerative colitis	3.04e-06	1.43e-05	CbGpPWpGaD
Nilotinib—KIT—Immune System—IL6—ulcerative colitis	3e-06	1.41e-05	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—JAK2—ulcerative colitis	3e-06	1.41e-05	CbGpPWpGaD
Nilotinib—CYP2C8—Metabolism—ADCY5—ulcerative colitis	2.99e-06	1.41e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—MMP9—ulcerative colitis	2.96e-06	1.39e-05	CbGpPWpGaD
Nilotinib—MAPK8—Signaling Pathways—TP53—ulcerative colitis	2.95e-06	1.39e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—CXCL8—ulcerative colitis	2.95e-06	1.39e-05	CbGpPWpGaD
Nilotinib—LCK—Immune System—STAT3—ulcerative colitis	2.94e-06	1.38e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—NFKB1—ulcerative colitis	2.93e-06	1.38e-05	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—RELA—ulcerative colitis	2.9e-06	1.37e-05	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—CXCL8—ulcerative colitis	2.88e-06	1.36e-05	CbGpPWpGaD
Nilotinib—MAPK11—Signaling Pathways—TGFB1—ulcerative colitis	2.86e-06	1.34e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Immune System—IL6—ulcerative colitis	2.84e-06	1.34e-05	CbGpPWpGaD
Nilotinib—BRAF—Signaling Pathways—TGFB1—ulcerative colitis	2.83e-06	1.33e-05	CbGpPWpGaD
Nilotinib—ABCG2—Metabolism—PTGS2—ulcerative colitis	2.82e-06	1.33e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—IL2—ulcerative colitis	2.82e-06	1.33e-05	CbGpPWpGaD
Nilotinib—MAP2K5—Signaling Pathways—TP53—ulcerative colitis	2.81e-06	1.32e-05	CbGpPWpGaD
Nilotinib—KIT—Signaling Pathways—STAT3—ulcerative colitis	2.78e-06	1.31e-05	CbGpPWpGaD
Nilotinib—KIT—Disease—IL6—ulcerative colitis	2.77e-06	1.3e-05	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—IL2—ulcerative colitis	2.76e-06	1.3e-05	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—CXCL8—ulcerative colitis	2.73e-06	1.29e-05	CbGpPWpGaD
Nilotinib—LCK—Disease—STAT3—ulcerative colitis	2.71e-06	1.28e-05	CbGpPWpGaD
Nilotinib—MAPK8—Signaling Pathways—IL6—ulcerative colitis	2.7e-06	1.27e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—MMP9—ulcerative colitis	2.66e-06	1.25e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—NFKB1—ulcerative colitis	2.64e-06	1.24e-05	CbGpPWpGaD
Nilotinib—CYP2B6—Metabolism—PPARG—ulcerative colitis	2.63e-06	1.24e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—STAT3—ulcerative colitis	2.63e-06	1.24e-05	CbGpPWpGaD
Nilotinib—CYP2D6—Metabolism—ABCB1—ulcerative colitis	2.63e-06	1.24e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Disease—IL6—ulcerative colitis	2.62e-06	1.24e-05	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—IL2—ulcerative colitis	2.61e-06	1.23e-05	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—MMP9—ulcerative colitis	2.61e-06	1.23e-05	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism—ABCB1—ulcerative colitis	2.61e-06	1.23e-05	CbGpPWpGaD
Nilotinib—ABCB1—Metabolism—ADCY5—ulcerative colitis	2.6e-06	1.23e-05	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—JAK2—ulcerative colitis	2.59e-06	1.22e-05	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—NFKB1—ulcerative colitis	2.58e-06	1.22e-05	CbGpPWpGaD
Nilotinib—KIT—Signaling Pathways—TGFB1—ulcerative colitis	2.58e-06	1.21e-05	CbGpPWpGaD
Nilotinib—MAP2K5—Signaling Pathways—IL6—ulcerative colitis	2.57e-06	1.21e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Immune System—IL6—ulcerative colitis	2.56e-06	1.21e-05	CbGpPWpGaD
Nilotinib—LCK—Disease—TGFB1—ulcerative colitis	2.52e-06	1.19e-05	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—RELA—ulcerative colitis	2.51e-06	1.18e-05	CbGpPWpGaD
Nilotinib—LYN—Immune System—IL6—ulcerative colitis	2.51e-06	1.18e-05	CbGpPWpGaD
Nilotinib—ABL1—Immune System—IL6—ulcerative colitis	2.49e-06	1.17e-05	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—MMP9—ulcerative colitis	2.47e-06	1.16e-05	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—PTGS1—ulcerative colitis	2.45e-06	1.16e-05	CbGpPWpGaD
Nilotinib—CYP2D6—Metabolism—ADCY5—ulcerative colitis	2.45e-06	1.15e-05	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—NFKB1—ulcerative colitis	2.45e-06	1.15e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—TGFB1—ulcerative colitis	2.44e-06	1.15e-05	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism—ADCY5—ulcerative colitis	2.43e-06	1.14e-05	CbGpPWpGaD
Nilotinib—MAPK14—Immune System—IL6—ulcerative colitis	2.38e-06	1.12e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—STAT3—ulcerative colitis	2.37e-06	1.12e-05	CbGpPWpGaD
Nilotinib—CYP2B6—Metabolism—ALB—ulcerative colitis	2.37e-06	1.11e-05	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—CXCL8—ulcerative colitis	2.36e-06	1.11e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Disease—IL6—ulcerative colitis	2.36e-06	1.11e-05	CbGpPWpGaD
Nilotinib—MAPK11—Signaling Pathways—TP53—ulcerative colitis	2.35e-06	1.11e-05	CbGpPWpGaD
Nilotinib—BRAF—Signaling Pathways—TP53—ulcerative colitis	2.33e-06	1.1e-05	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—STAT3—ulcerative colitis	2.32e-06	1.09e-05	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—IL2—ulcerative colitis	2.26e-06	1.06e-05	CbGpPWpGaD
Nilotinib—CYP2C8—Metabolism—PPARG—ulcerative colitis	2.23e-06	1.05e-05	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—CALM3—ulcerative colitis	2.21e-06	1.04e-05	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—STAT3—ulcerative colitis	2.2e-06	1.04e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—TGFB1—ulcerative colitis	2.2e-06	1.03e-05	CbGpPWpGaD
Nilotinib—MAPK11—Signaling Pathways—IL6—ulcerative colitis	2.15e-06	1.01e-05	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—TGFB1—ulcerative colitis	2.15e-06	1.01e-05	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—MMP9—ulcerative colitis	2.14e-06	1.01e-05	CbGpPWpGaD
Nilotinib—BRAF—Signaling Pathways—IL6—ulcerative colitis	2.13e-06	1e-05	CbGpPWpGaD
Nilotinib—KIT—Signaling Pathways—TP53—ulcerative colitis	2.12e-06	9.98e-06	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—NFKB1—ulcerative colitis	2.12e-06	9.96e-06	CbGpPWpGaD
Nilotinib—CYP2B6—Metabolism—PTGS2—ulcerative colitis	2.07e-06	9.75e-06	CbGpPWpGaD
Nilotinib—LCK—Immune System—IL6—ulcerative colitis	2.05e-06	9.67e-06	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—TGFB1—ulcerative colitis	2.04e-06	9.6e-06	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—TP53—ulcerative colitis	2.01e-06	9.45e-06	CbGpPWpGaD
Nilotinib—CYP2C8—Metabolism—ALB—ulcerative colitis	2e-06	9.43e-06	CbGpPWpGaD
Nilotinib—ABCB1—Metabolism—PPARG—ulcerative colitis	1.94e-06	9.14e-06	CbGpPWpGaD
Nilotinib—KIT—Signaling Pathways—IL6—ulcerative colitis	1.94e-06	9.14e-06	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—STAT3—ulcerative colitis	1.9e-06	8.95e-06	CbGpPWpGaD
Nilotinib—LCK—Disease—IL6—ulcerative colitis	1.9e-06	8.93e-06	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—IL6—ulcerative colitis	1.84e-06	8.65e-06	CbGpPWpGaD
Nilotinib—CYP2D6—Metabolism—PPARG—ulcerative colitis	1.83e-06	8.61e-06	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism—PPARG—ulcerative colitis	1.81e-06	8.54e-06	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—TP53—ulcerative colitis	1.81e-06	8.51e-06	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—TP53—ulcerative colitis	1.77e-06	8.34e-06	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—TGFB1—ulcerative colitis	1.76e-06	8.3e-06	CbGpPWpGaD
Nilotinib—CYP2C8—Metabolism—PTGS2—ulcerative colitis	1.75e-06	8.25e-06	CbGpPWpGaD
Nilotinib—ABCB1—Metabolism—ALB—ulcerative colitis	1.75e-06	8.22e-06	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—ABCB1—ulcerative colitis	1.72e-06	8.09e-06	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—TP53—ulcerative colitis	1.68e-06	7.9e-06	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—IL6—ulcerative colitis	1.65e-06	7.79e-06	CbGpPWpGaD
Nilotinib—CYP2D6—Metabolism—ALB—ulcerative colitis	1.64e-06	7.75e-06	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism—ALB—ulcerative colitis	1.63e-06	7.68e-06	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—IL6—ulcerative colitis	1.62e-06	7.63e-06	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—ADCY5—ulcerative colitis	1.6e-06	7.55e-06	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—IL6—ulcerative colitis	1.54e-06	7.23e-06	CbGpPWpGaD
Nilotinib—ABCB1—Metabolism—PTGS2—ulcerative colitis	1.53e-06	7.19e-06	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—TP53—ulcerative colitis	1.45e-06	6.83e-06	CbGpPWpGaD
Nilotinib—CYP2D6—Metabolism—PTGS2—ulcerative colitis	1.44e-06	6.78e-06	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism—PTGS2—ulcerative colitis	1.43e-06	6.72e-06	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—IL6—ulcerative colitis	1.33e-06	6.25e-06	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—PPARG—ulcerative colitis	1.2e-06	5.63e-06	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—ALB—ulcerative colitis	1.08e-06	5.06e-06	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—PTGS2—ulcerative colitis	9.41e-07	4.43e-06	CbGpPWpGaD
